Project Grant R21AI174130

Award Date 12/12/22
Completion Date 11/30/25
Dollars Obligated $1.7M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98122, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $228,435 Project Grant (CFDA 93.855) to the University of California, Irvine (UC Irvine) to conduct research on the role of the APOBEC3B enzyme in the innate immune response against RNA viruses. The goal of the research is to identify novel antiviral functions of APOBEC3B that do not require its deaminase activity, with a focus on understanding how APOBEC3B modulates the PKR signaling pathway to promote translation...
This $477,226 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to discover novel antiviral systems in microbial eukaryotes. The project will focus on understanding how the amoeba genus Acanthamoeba defends against members of the Megavirales family of giant viruses, and will expand this research to other microbial eukaryotes. The project will leverage cutting-edge AI-driven...
The Project Grant award R01AI184293, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural basis of HIV-1 cap hypermethylation and its role in viral gene expression and immune regulation. The $696,828 award to the Regents of the University of Minnesota aims to reveal how the HIV-1 RNA cap structure and its interactions with host factors like the RNA...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $854,360.00 to Trustees of Boston University Medical Campus to investigate the role of RNA modifications in chronic inflammation among people living with HIV on antiretroviral therapy. The key objectives are to determine how the interaction between HIV RNA modifications and "proinflammatory" RNA-binding...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,112,961 to the University of Chicago to investigate the mechanisms by which certain genetic variants of the H2-O/DO molecule regulate the major histocompatibility complex class II (MHCII) antigen presentation pathway. The research aims to identify novel modulators of the MHCII pathway that can influence the...
This $2,535,942 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to study the viral and host determinants of donor-specific anti-HIV/SIV immunity mediated by APOBEC3 enzymes. The primary grantee, Texas Biomedical Research Institute, will integrate diverse viral and host datasets using computational and experimental techniques to identify the molecular determinants...
This Project Grant award of $154,568.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to uncover the mechanisms by which the innate immune effector TRIM56 restricts a broad range of viruses, with a focus on HIV-1. The award recipient, The Children's Hospital Corporation doing business as Boston Children's Hospital, will conduct biochemical and structural biology investigations to...
This $492,980 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate how variations in the HIV Rev-Rev Response Element (Rev-RRE) regulatory mechanism contribute to viral transmission and latency. The project aims to: 1) define the role of Rev-RRE variation in navigating the sexual transmission bottleneck, 2) explore the contribution of the Rev-RRE...
This Project Grant award, totaling $248,999.00, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859). The project aims to investigate the role of mitochondrial-endoplasmic reticulum (ER) contact sites, known as mitochondria/ER contacts (MERCs), in regulating the release of mitochondrial DNA (mtDNA) and coordinating innate immune responses to viral infections. Specifically, the research will examine...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under CFDA 93.859 Biomedical Research and Research Training program, will support a research program focused on uncovering and studying antiviral effector proteins in diverse species. The $125,000 award, effective from Sep 1, 2024 to Aug 31, 2026, will fund three key research aims: Perform structural homology searches to define patterns of gene capture in diverse viruses and identify structural...

REVERSE TRANSCRIPTASE-MEDIATED EXPANSION OF THE HOST INNATE IMMUNE SYSTEM - PROJECT SUMMARY LARGE EFFECT MUTATIONS IN INNATE IMMUNITY GENES CAN HAVE DRAMATIC EFFECTS ON INFECTIOUS DISEASE SUSCEPTIBILITY AND OUTCOME. IN ADDITION, THE GENETIC DETERMINANTS OF MORE SUBTLE AND WIDESPREAD VARIATION IN AN INDIVIDUAL'S SUSCEPTIBILITY AND IMMUNE RESPONSE TO VIRAL INFECTIONS HAS BEEN STUDIED IN THE CONTEXT OF MUTATIONS IN THE MANY KNOWN INNATE IMMUNITY GENES. WE PROPOSE THAT THERE ARE NEW POLYMORPHIC INNATE IMMUNE GENES CREATED BY RETROVIRUSES (SO CALLED 'RETROCOPIES') IN THE GENOME OF MANY INDIVIDUALS WHICH ARE TYPICALLY OVERLOOKED, AND WHICH HAVE THE CAPACITY TO MODULATE AN INDIVIDUAL'S IMMUNE RESPONSE. THOUSANDS OF YOUNG AND OLD RETROCOPIES ARE PRESENT IN EACH HUMAN GENOME AND THEIR NUMBER AND SEQUENCES DIFFER AMONG INDIVIDUALS IN A POPULATION. UNTIL NOW, OLD RETROCOPIES HAVE LARGELY BEEN IGNORED AS PSEUDOGENES, WHILE YOUNG RETROCOPIES HAVE BEEN UNDERSTUDIED DUE TO TECHNICAL CHALLENGES OF ACCURATE IDENTIFICATION INHERENT IN THE MOST COMMON SEQUENCING TECHNOLOGIES. A PIONEERING STUDY IN OUR LAB SHOWED THAT HUMAN AND OTHER PRIMATE GENOMES CONTAIN RETROCOPIES OF THE APOBEC3 FAMILY OF VIRAL RESTRICTION FACTORS THAT ARE TRANSCRIBED AND CAPABLE OF RESTRICTING VIRUS REPLICATION IN VITRO. OUR MORE RECENT PRELIMINARY DATA REVEALED EXTENSIVE RETROCOPYING OF ADDITIONAL ANTIVIRAL GENE FAMILIES WITHIN HUMANS AND OTHER PRIMATE SPECIES, SUGGESTING THE RECENT RETROCOPYING OF VIRAL RESTRICTION AND HOST DEPENDENCY FACTORS MAY BE WIDESPREAD. FURTHER, SOME OF THESE RETROCOPIES ARE VERY YOUNG - PRESENT IN ONLY SOME HUMANS - AND COULD REPRESENT AN UNAPPRECIATED SOURCE OF INDIVIDUAL VARIATION IN SUSCEPTIBILITY OR RESISTANCE TO VIRAL INFECTION. WITH A COMBINATION OF COMPUTATIONAL BIOLOGY, IN VITRO VIROLOGY AND BIOCHEMISTRY, AND HIGH THROUGHPUT FUNCTIONAL ASSAYS, WE WILL IDENTIFY YOUNG RETROCOPIES OF VIRUS-INTERACTING GENES THAT ARE PRESENT IN ONLY SOME HUMANS AND TEST THESE NEW GENES' ABILITY TO ENHANCE OR IMPEDE THE INNATE IMMUNE SYSTEM'S ANTIVIRAL RESPONSE. TO TEST OUR HYPOTHESIS THAT RETROCOPY EXPANSIONS MODIFY IMMUNE SYSTEM FUNCTION, WE WILL: (1) IDENTIFY YOUNG, POLYMORPHIC RETROCOPIES OF HOST DEPENDENCY AND RESTRICTION FACTOR GENES IN HUMANS. (2) CHARACTERIZE TRANSCRIPTION AND ANTIVIRAL FUNCTIONS OF POLYMORPHIC HOST DEPENDENCY AND RESTRICTION FACTOR RETROCOPIES, EITHER AS RESTRICTION FACTORS OR DEPENDENCY FACTORS THAT EVADE VIRAL CO-OPTION. (3) IDENTIFY RETROCOPIES THAT ACT AS DOMINANT NEGATIVE INHIBITORS OF THEIR PARENTAL ANTIVIRAL GENES THEREBY INHIBITING THE INNATE IMMUNE SYSTEM AND PROMOTING VIRAL REPLICATION. THIS RESEARCH WILL DISCOVER NEW INNATE IMMUNE GENES AND FOUND A NEW DIRECTION IN UNDERSTANDING THE GENETIC DETERMINANTS OF AN INDIVIDUAL'S SUSCEPTIBILITY AND IMMUNE RESPONSE TO VIRUS INFECTION.

Posted 12/12/22, 12:00 AM